Know Cancer

or
forgot password

Liver Tumour Studies - Hepatoblastoma and Hepatocellular Carcinoma


Phase 3
N/A
16 Years
Open (Enrolling)
Both
Liver Cancer

Thank you

Trial Information

Liver Tumour Studies - Hepatoblastoma and Hepatocellular Carcinoma


OBJECTIVES:

- Compare the efficacy of cisplatin with or without doxorubicin in terms of tumor
response, complete resection rate, overall survival, and event free survival in
children with standard risk hepatoblastoma.

- Compare the toxicity of cisplatin with or without doxorubicin in this patient
population.

- Evaluate whether an intensive multiagent regimen including carboplatin, cisplatin, and
doxorubicin improves the response rate to chemotherapy and subsequent resection rate of
children with high risk hepatoblastoma or hepatocellular carcinoma.

OUTLINE: This is a randomized, multicenter study. All hepatoblastoma patients are intended
to be treated with primary chemotherapy. Hepatoblastoma patients are stratified by risk
(standard vs high).

Patients receive cisplatin IV over 24 hours on day 1, beginning within 15 days of diagnosis.
Standard risk patients are then randomized to one of two treatment arms. High risk
hepatoblastoma patients and hepatocellular carcinoma patients receive a separate multiagent
regimen.

- Arm I: Patients receive cisplatin IV over 24 hours and doxorubicin IV over 48 hours
beginning on day 15. Treatment repeats every 21 days for a maximum of 5 courses. Tumor
response is evaluated prior to the second course. Patients with responsive disease
receive the remaining 2 courses of the preoperative phase, then undergo delayed primary
surgery if their tumors are deemed resectable, prior to receiving 2 additional courses
of chemotherapy. Patients whose tumors are still unresectable after 3 courses receive 2
more courses of chemotherapy, then undergo surgery if feasible. Patients with stable
disease are considered for radical surgery or salvage chemotherapy. Patients with
unresectable tumors after 5 courses may be considered for liver transplant or salvage
chemotherapy.

- Arm II: Patients receive cisplatin IV over 24 hours every 15 days for a maximum of 5
additional courses. Tumor response is evaluated after the second course. Patients with
responsive disease receive another 2 courses of cisplatin. Patients with resectable
tumors after 4 courses undergo delayed primary surgery, then receive 2 more courses of
cisplatin. Patients whose tumors are still unresectable after 4 courses receive 2 more
courses of cisplatin, then undergo surgery if their tumors are resectable. Patients
with stable disease may be moved to the high risk regimen or considered for radical
surgery. Patients with unresectable tumors after 6 courses may be considered for liver
transplant or salvage chemotherapy.

Patients with high risk hepatoblastoma or unresectable hepatocellular carcinoma receive
cisplatin IV over 24 hours on days 29, 57, and 85, and carboplatin IV over 1 hour followed
by doxorubicin IV over 48 hours on days 15, 43, and 71. Patients with responsive resectable
disease undergo surgery either after day 43 or within 3 weeks of day 85 of preoperative
chemotherapy, then receive another 2 courses of carboplatin and doxorubicin on days 1 and 29
post surgery, and one more course of cisplatin on day 15 post surgery, for a total of 5
courses each. Patients with responsive but unresectable disease after day 85 also receive 2
more courses of carboplatin and doxorubicin alternating with 1 course of cisplatin.
Definitive surgery will be re-considered after these further courses of chemotherapy.
Patients with stable disease at day 43 or a tumor that remains unresectable after completion
of chemotherapy may be considered for liver transplant.

Patients with a resectable hepatocellular carcinoma have primary surgery followed by
alternating courses of cisplatin, and carboplatin and doxorubicin for a total of 4 courses
of cisplatin and 3 courses of carboplatin and doxorubicin.

Patients are followed every 2-3 months for 2 years, every 6 months for 1 year, then annually
thereafter.

PROJECTED ACCRUAL: A total of 170-260 patients (85-130 patients per treatment arm) will be
accrued for this study over 5.5 years.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically proven hepatoblastoma or hepatocellular carcinoma

- Diagnostic surgical biopsy strongly recommended for all patients and mandatory
for the following:

- Children under 6 months of age

- Children over 3 years of age

- Patients with a normal serum alfa-fetoprotein (alfa-FP)

- Compatible imaging and raised serum alfa-FP level mandatory if no biopsy
performed

- Standard risk disease:

- Tumors involving no more than 3 hepatic sections

- No extrahepatic abdominal disease

- No metastases

- High risk disease:

- Tumors involving all 4 hepatic sections AND/OR

- Evidence of extrahepatic metastases or abdominal disease

- Presence or absence of metastatic disease must be documented by chest x-ray and/or
lung CT scan

PATIENT CHARACTERISTICS:

Age:

- 16 and under at diagnosis

Performance status:

- Not specified

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- Not specified

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- See Disease Characteristics

- Prior surgery allowed

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Primary Purpose: Treatment

Outcome Measure:

Tumor response

Safety Issue:

No

Principal Investigator

Giorgio Perilongo, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Azienda Ospedaliera di Padova

Authority:

United States: Federal Government

Study ID:

CDR0000067091

NCT ID:

NCT00003912

Start Date:

June 1998

Completion Date:

Related Keywords:

  • Liver Cancer
  • stage I childhood liver cancer
  • stage II childhood liver cancer
  • stage III childhood liver cancer
  • stage IV childhood liver cancer
  • recurrent childhood liver cancer
  • childhood hepatoblastoma
  • childhood hepatocellular carcinoma
  • Liver Neoplasms
  • Hepatoblastoma
  • Carcinoma, Hepatocellular

Name

Location